In clinical trials, mTOR inhibitors (everolimus), dual PI3K/mTOR inhibitors, and ATP-competitive mTORC1/2 inhibitors are used for several types of tumors, including those associated with GC [171]. This evidence concerns the gene PIK3CD and gastric cancer.